FDA’s Center for Veterinary Medicine deems TriviumVet’s feline HCM program eligible for expanded conditional approval pathway

TriviumVet™ are delighted to announce that the Food and Drug Administration’s Center for Veterinary Medicine has determined that our feline hypertrophic cardiomyopathy (HCM) therapeutic candidate, Felycin™ can pursue the expanded conditional approval pathway. US Congress granted the FDA a limited expansion of the conditional approval pathway for certain new animal drugs under the 2018 reauthorization […]

TriviumVet announce collaboration with the Dog Aging Project

TriviumVet, today announced an exciting research collaboration with the Dog Aging Project, TRIAD Trial. What is the Dog Aging Project? The Dog Aging Project is an innovative initiative based in the United States that brings together a community of dogs, owners, veterinarians, researchers, and volunteers to carry out the most ambitious canine health study in […]

TriviumVet announce publication of recent research into gastric acid suppression in dogs

TriviumVet are delighted to announce the publication of a clinical study assessing our first product in development, a gastric acid suppressant to treat gastric ulceration in dogs. Unmet treatment need Worldwide there are no veterinary registered pharmaceutical treatments for gastric ulceration in dogs. Gastric ulceration is a well-recognized disorder in canine veterinary practice, often arising […]

TriviumVet advance their first feline product, a potential treatment for HCM in cats

TriviumVet commence clinical study of first-in-disease treatment for HCM in cats We are delighted to announce the initiation of a ground-breaking clinical study in client-owned cats to evaluate the effectiveness of our patented delayed-release rapamycin formulation (TRIV-203F) in treating hypertrophic cardiomyopathy (HCM). Rapamycin background Results of previous laboratory animal studies and effects observed in human […]